Ginkgo Bioworks Announces Strategic Partnership with Inductive Bio and Tangible to Revolutionize Drug Discovery with AI-Driven Lab-in-the-Loop Technology

Ginkgo Bioworks has partnered with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery accessible across the industry. The partnership combines high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service, aiming to improve ADMET optimization and reduce iteration times. The services are available now and tailored for pharmaceutical and biotech teams.

Ginkgo Bioworks (NYSE: DNA), in collaboration with Inductive Bio and Tangible Scientific, has launched a strategic partnership to deploy AI-driven lab-in-the-loop workflows across the biopharma industry. This new service aims to enhance drug discovery by integrating high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a single, seamless platform [1].

The partnership combines several core capabilities:
- Ginkgo Datapoints' rapid ADME profiling services, which deliver high-quality readouts on lead candidates and library-scale compound sets.
- Inductive Bio's model-driven chemistry design platform, which allows chemists to explore and rank design ideas using fine-tuned ADMET prediction models.
- Tangible Scientific's API-enabled compound management platform, which orchestrates the secure storage, handling, and rapid movement of customer compounds.

Together, these capabilities aim to streamline the drug discovery process by moving from in-silico compound designs to validated experimental results in a single, digitally-enabled workstream. This integration is designed to reduce synthesis cycles, speed up turnarounds, and lower overall drug discovery costs [1].

The partnership addresses the current fragmentation in drug discovery, where compounds often need to be moved across vendors and continents, introducing delays and coordination bottlenecks. By tightly coupling model-driven design with streamlined logistics, the partnership aims to make AI/ML-ready assay data available in real-time, enabling scientists to iterate quickly and focus on their core expertise—discovering treatments for patients [1].

The services are now available and tailored for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times on programs and across portfolios. This initiative supports the FDA's push for faster, more efficient development timelines, onshored manufacturing and services, greater use of AI tools, and adoption of non-animal approaches in preclinical testing [1].

References:
[1] https://www.morningstar.com/news/pr-newswire/20250820ne54923/ginkgo-datapoints-tangible-scientific-and-inductive-bio-partner-to-deploy-ai-driven-lab-in-the-loop-workflows-across-the-biopharma-industry